SEC Form 4 · accession 0001213900-17-008160
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John K Bell
Director
Period of report
Aug 1, 2017
Accepted (ET)
Aug 2, 2017 · 9:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2017 | C | 25,000 | — | A | 74,737 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exchangeable SharesF1 | — | Aug 1, 2017 | C | 25,000 | D | — | — | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1Exchangeable Shares are shares of a wholly-owned subsidiary of the Issuer that are exchangeable at any time for shares of common stock in the Issuer on the basis of one Exchangeable Share for one share of common stock.